Drug Type Small molecule drug |
Synonyms AHBP, AHDP, AHHexBP + [6] |
Target |
Action inhibitors |
Mechanism Bone resorption factor inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date Italy (01 Jan 2002), |
RegulationOrphan Drug (United States) |
Molecular FormulaC6H17NNaO7P2 |
InChIKeyQFABQPWMXJMQES-UHFFFAOYSA-N |
CAS Registry80729-79-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Neridronate Sodium |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Osteitis Deformans | Italy | 01 Jan 2002 | |
Osteogenesis Imperfecta | Italy | 01 Jan 2002 |
Not Applicable | 8 | orfbbkjpxz(aezgkrnmwl) = ykudyeiuqh rjnhpxjtwb (bzwqvfpqah, 0.19) | Positive | 24 Mar 2022 | |||
orfbbkjpxz(aezgkrnmwl) = oltidtllut rjnhpxjtwb (bzwqvfpqah, 0.164) | |||||||
Not Applicable | - | (bxeyacammr) = reported in 47.3% of patients younger than 20 years and in 22.8% of those older than 20 years cgogendchd (mvzyqenhmi ) View more | Positive | 14 Jun 2017 |